{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:07:38Z","timestamp":1792789658363,"version":"4.5.0"},"reference-count":16,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T00:00:00Z","timestamp":1718409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Bristol Myers Squibb and Pfizer, Inc."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: Oral anticoagulants (OACs), such as apixaban and warfarin, are indicated for reducing the risk of recurrent venous thromboembolism (VTE) and are often initiated in the hospital. The aim of this study was to evaluate OAC continuity from inpatient to outpatient settings and the risk of recurrent VTE among patients with an initial event. Methods: This retrospective cohort study utilized hospital charge data and medical and prescription claims from 1 July 2016 to 31 December 2022 to identify adults treated with apixaban or warfarin while hospitalized for VTE. Patients were followed to assess switching or discontinuation post-discharge and the risk of recurrent VTE. The index date was the date of the first apixaban or warfarin claim within 30 days post-discharge. Results: Of the 19,303 eligible patients hospitalized with VTE, 85% (n = 16,401) were treated with apixaban and 15% (n = 2902) received warfarin. After discharge, approximately 70% had \u22651 fill for their respective apixaban or warfarin therapy. The cumulative incidence of discontinuation over the 6 months following index was 50.5% and 52.2% for the apixaban and warfarin cohorts, respectively; the cumulative incidence of switching was 6.0% and 20.9%, respectively. The incidence rates of recurrent VTE were 1.2 and 2.5 per 100 person-years for the apixaban and warfarin cohorts, respectively. Conclusions: The majority of patients continued their apixaban or warfarin therapy following hospital discharge; however, a considerable proportion either switched or discontinued OAC upon transitioning from inpatient care. Among those who continued therapy, discontinuation, switch, and recurrent VTE occurred less often with apixaban vs. warfarin.<\/jats:p>","DOI":"10.3390\/jcm13123512","type":"journal-article","created":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T06:29:43Z","timestamp":1718605783000},"page":"3512","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Post-Discharge Treatment Patterns among Patients Treated with Apixaban or Warfarin during Hospitalization for Venous Thromboembolism (VTE)"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7193-3751","authenticated-orcid":false,"given":"James C.","family":"Coons","sequence":"first","affiliation":[{"name":"Department of Pharmacy, UPMC Presbyterian Hospital, Pittsburgh, PA 15213, USA"},{"name":"Department of Pharmacy and Therapeutics, University of Pittsburgh School of Pharmacy, Pittsburgh, PA 15261, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0385-8657","authenticated-orcid":false,"given":"Vamshi Ruthwik","family":"Anupindi","sequence":"additional","affiliation":[{"name":"IQVIA Inc., Durham, NC 27703, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riddhi","family":"Doshi","sequence":"additional","affiliation":[{"name":"IQVIA Inc., Durham, NC 27703, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9346-6202","authenticated-orcid":false,"given":"Mitch","family":"DeKoven","sequence":"additional","affiliation":[{"name":"IQVIA Inc., Durham, NC 27703, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Dai","sequence":"additional","affiliation":[{"name":"Pfizer, New York, NY 10001, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7248-9712","authenticated-orcid":false,"given":"Cristina","family":"Russ","sequence":"additional","affiliation":[{"name":"Pfizer, New York, NY 10001, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Stellhorn","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Lawrenceville, NJ 08543, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Cheng","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Lawrenceville, NJ 08543, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-8028-0195","authenticated-orcid":false,"given":"Liucheng","family":"Shi","sequence":"additional","affiliation":[{"name":"IQVIA Inc., Durham, NC 27703, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serina","family":"Deeba","sequence":"additional","affiliation":[{"name":"Pfizer, New York, NY 10001, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dionne M.","family":"Hines","sequence":"additional","affiliation":[{"name":"Pfizer, New York, NY 10001, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,6,15]]},"reference":[{"key":"ref_1","unstructured":"(2023, August 08). Agency for Healthcare Research and Quality. Healthcare Cost and Utilization Project (HCUP): HCUP Databases. National (Nationwide) Inpatient Sample (NIS) Database Documentation, Available online: https:\/\/hcup-us.ahrq.gov\/db\/nation\/nis\/nisdbdocumentation.jsp."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/nrcardio.2015.83","article-title":"Epidemiology of venous thromboembolism","volume":"12","author":"Heit","year":"2015","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"832.e13","DOI":"10.1016\/j.amjmed.2013.02.024","article-title":"Incidence of and mortality from venous thromboembolism in a real-world population: The Q-VTE Study Cohort","volume":"126","author":"Tagalakis","year":"2013","journal-title":"Am. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"S495","DOI":"10.1016\/j.amepre.2009.12.017","article-title":"Venous thromboembolism: A public health concern","volume":"38","author":"Beckman","year":"2010","journal-title":"Am. J. Prev. Med."},{"key":"ref_5","unstructured":"Centers for Disease Control and Prevention (2023, June 28). Venous Thromboembolism (Blood Clots), Available online: https:\/\/www.cdc.gov\/blood-clots\/data-research\/facts-stats\/index.html."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"4693","DOI":"10.1182\/bloodadvances.2020001830","article-title":"American Society of Hematology 2020 guidelines for management of venous thromboembolism: Treatment of deep vein thrombosis and pulmonary embolism","volume":"4","author":"Ortel","year":"2020","journal-title":"Blood Adv."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.thromres.2020.05.036","article-title":"Adherence to and persistence with direct oral anticoagulant therapy among patients with new onset venous thromboembolism receiving extended anticoagulant therapy and followed by a centralized anticoagulation service","volume":"193","author":"Packard","year":"2020","journal-title":"Thromb. Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1080\/21548331.2020.1769988","article-title":"Clinical characteristics and treatment patterns of patients with venous thromboembolism (VTE) transitioning from hospital to post-discharge settings","volume":"48","author":"Burton","year":"2020","journal-title":"Hosp. Pract."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s12325-015-0271-8","article-title":"Transitions in the Prophylaxis, Treatment and Care of Patients with Venous Thromboembolism","volume":"33","author":"Lenchus","year":"2016","journal-title":"Adv. Ther."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1001\/jama.2012.216607","article-title":"Association between quality improvement for care transitions in communities and rehospitalizations among Medicare beneficiaries","volume":"309","author":"Brock","year":"2013","journal-title":"JAMA"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/0895-4356(93)90103-8","article-title":"Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: Differing perspectives","volume":"46","author":"Romano","year":"1993","journal-title":"J. Clin. Epidemiol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2147\/CEOR.S179080","article-title":"Systematic literature review of treatment patterns for venous thromboembolism patients during transitions from inpatient to post-discharge settings","volume":"11","author":"Trocio","year":"2019","journal-title":"Clin. Outcomes Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e234059","DOI":"10.1001\/jamanetworkopen.2023.4059","article-title":"Trends in the Use of Oral Anticoagulants for Adults with Venous Thromboembolism in the US, 2010\u20132020","volume":"6","author":"Iyer","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1001\/jama.2022.1920","article-title":"Association of Type of Oral Anticoagulant Dispensed with Adverse Clinical Outcomes in Patients Extending Anticoagulation Therapy Beyond 90 Days After Hospitalization for Venous Thromboembolism","volume":"327","author":"Pawar","year":"2022","journal-title":"JAMA"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1111\/cts.13433","article-title":"Comparative effectiveness and safety of extended anticoagulant therapy among Medicare beneficiaries with venous thromboembolism","volume":"16","author":"Park","year":"2023","journal-title":"Clin. Transl. Sci."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1093\/ajhp\/zxz307","article-title":"Comparative effectiveness and safety of apixaban versus warfarin in patients with venous thromboembolism","volume":"77","author":"Dawwas","year":"2020","journal-title":"Am. J. Health Syst. Pharm."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/12\/3512\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:59:20Z","timestamp":1760108360000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/12\/3512"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,15]]},"references-count":16,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,6]]}},"alternative-id":["jcm13123512"],"URL":"https:\/\/doi.org\/10.3390\/jcm13123512","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,15]]}}}